Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL). METHODS: We conducted 2 parallel phase I/II studies (ClinicalTrials.gov...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Ramos, Carlos A., Grover, Natalie S., Beaven, Anne W., Lulla, Premal D., Wu, Meng-Fen, Ivanova, Anastasia, Wang, Tao, Shea, Thomas C., Rooney, Cliona M., Dittus, Christopher, Park, Steven I., Gee, Adrian P., Eldridge, Paul W., McKay, Kathryn L., Mehta, Birju, Cheng, Catherine J., Buchanan, Faith B., Grilley, Bambi J., Morrison, Kaitlin, Brenner, Malcolm K., Serody, Jonathan S., Dotti, Gianpietro, Heslop, Helen E., Savoldo, Barbara
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2020
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655020/
https://ncbi.nlm.nih.gov/pubmed/32701411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01342
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料